Skip to content
value.today

Saliogen Therapeutics, Inc.

Total raised
$152 M
2 rounds on record
Latest round
$132 M
Nov 2021
First round on record
Feb 2021
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Saliogen Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2021$132 MNo. 2$50 to $250 million

Saliogen Therapeutics, Inc.: Raise no. 2, Nov 2021

Investors in this round

24 investors had bought by the notice of Apr 18, 2022: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$132 M of $132 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joseph Higgins · Executive Officer, Director
  • Raymond Tabibiazar · Executive Officer, Director
  • Craig Gordon · Director
  • Sean Stalfort · Director
  • Sukumar Nagendran · Director · While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proce

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.”

Signed by Raymond Tabibiazar, Chief Executive Officer. Newest notice filed Apr 18, 2022 (1 amendment). Read the notice at the SEC.

equitySEC
Feb 2021$20 MNo. 1$10 to $50 million

Saliogen Therapeutics, Inc.: Raise no. 1, Feb 2021

Investors in this round

3 investors had bought by the notice of Feb 18, 2021: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joseph Higgins · Executive Officer, Director
  • Raymond Tabibiazar · Executive Officer, Director
  • Sean Stalfort · Director
  • Sukumar Nagendran · Director · While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proce

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • BTIG, LLC (CRD 122225) · San Francisco,, CaliforniaSold in CA, IL, NJ, VA

Remarks in the notice

  • On the use of proceeds: “While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.”

Signed by Raymond Tabibiazar, Chief Executive Officer. Newest notice filed Feb 18, 2021. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Saliogen Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2022).

    SEC Form D · Apr 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Apr 2022

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Saliogen Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Saliogen Therapeutics, Inc.
NameRoleNamed in
Joseph HigginsExecutive officerApr 2022
Raymond TabibiazarExecutive officerApr 2022
Craig GordonDirectorApr 2022
Joseph HigginsDirectorApr 2022
Raymond TabibiazarDirectorApr 2022
Sean StalfortDirectorApr 2022
Sukumar NagendranWhile no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceApr 2022